Welcome to the Zenith Epigenetics Hub On AGORACOM
Zenith's Lead Pan Selective BET Inhibitor ZEN-3694 is Currently Being Evaluated in Phase 1 Prostate Cancer Clinical Trials
fast facts
- name Zenith Epigenetics
- symbol ZZXY
- exchange OTCBB
- financials View Filings
- shares outstanding 125,580,800
- industry Technology & Medical
- transfer agent Computershare Trust Company of Canada
- website http://www.zenithepigenet...
recent updates
-
WebLink -
BIO International Slides June 4, 2018 -
-
WebLink -
BIO-Europe presentation March 13, 2018 -
WebLink -
Biotech Showcase January 8, 2018 Slides -
WebLink -
Zenith AGM 12 Dec 2017 - Q&A
most recent messages
top rated messages